Metabolism Agentic Intelligence Atlas (MAIA)MAIA

Pioneering Whole-Body Spatial Intelligence

Live Federated real-world evidence network
50 states7 Major Integrated Delivery Networks29M patient livesde-identifiedextending internationally
Contributing health systems
AI agentscontinuously traversing evidence and surfacing auditable hypotheses
Toward biomedical superintelligence, one auditable hypothesis at a time
50Scientific discoveries
16Organ systems
25Studies published
356Press articles
29M patient lives
100+ patents and applications
10+ FDA-cleared or breakthrough products
Scroll
Timelapse · the arc of discovery

The findings, reported.

Findings from real-world care, and the reporting that followed.

Explore the research atlas ↓

Latest coverage

EMJ GOLD

Tirzepatide linked to more lean mass loss than semaglutide

The preprint asks how the composition of weight loss differs between medicines, extending the focus beyond total kilograms lost.

This suggests that patients shouldn’t simplistically be thinking, ‘I want to lose X amount of weight and I’ll go with the option that delivers greater weight loss’
Venky Soundararajan, nference, to Reuters
Published study
Cardiovascular Business

A closer look at how semaglutide protects the heart

Dose and weight change show different associations with cardiovascular outcomes in a real-world landmark analysis.

These findings suggest a cardioprotective role of semaglutide which may be related to attained dose but is not explained simply by the amount of weight loss achieved while on therapy
The study authors
Published study
Reuters

Semaglutide use in pregnancy may not be cause for alarm

In a preprint of 572 pregnancies with semaglutide prescribed before conception, complications, preterm birth, stillbirth and newborn Apgar scores did not differ between women who continued the drug and those who stopped.

These observations motivate the need for larger retrospective and prospective studies to rigorously establish the safety of semaglutide exposure during pregnancies
nference researchers
LA Times Studios

Why Patients Left Approved Obesity Drugs for Gray-Market Retatrutide

A look at documented use and the limits of observational comparisons.

This pattern suggests that at least some patients received a biologically active product capable of producing incretin-like cardiovascular pharmacology, but without the degree of weight-loss efficacy observed under a clinical-trial protocol
Venky Soundararajan, nference
Dentistry IQ

New data from preprint study analyzed GLP-1 medications for negative oral health effects

A dental trade report on a preprint of oral and dental conditions after semaglutide or tirzepatide, with an outside caution against reading association as causation.

While xerostomia deserves our attention, this early research is also an important reminder not to confuse association with causation or assume that GLP-1 use inherently leads to dental disease
Pamela Maragliano, chief editor of Dental Economics — not involved in the study
HealthDay

Menopause Hormone Therapy Might Boost GLP-1 Weight Loss Results, Study Says

Women on menopause hormone therapy lost more weight on semaglutide in a large real-world cohort presented at The Menopause Society; the signal was weaker with tirzepatide and needs prospective confirmation.

These findings need to be confirmed in adequately designed prospective trials, and it’s important to remember that weight loss is not an indication for menopause hormone therapy
Regina Castaneda, Mayo Clinic Florida, lead researcher
Medical News Today

Ozempic plus hormone therapy may help boost weight loss at menopause

The lead researcher explains why hormone therapy was linked to greater weight loss with semaglutide but not clearly with tirzepatide, and why the results are hypothesis-generating.

While encouraging, these results should be viewed as hypothesis-generating
Regina Castaneda, Mayo Clinic Florida, lead researcher
Published abstract
Healthline

Microdosing GLP-1s Like Wegovy, Zepbound May Still Lead to Weight Loss

Patients who stayed on starter doses still lost weight in the real-world comparison; an outside surgeon describes seeing the same in practice.

I have seen this in my own practice. Although these starter doses are generally intended to help patients adjust to the medication, some people may experience meaningful weight loss even at these lower doses
Mir Ali, MemorialCare — not involved in the study
Published study
Epocrates

Could hormone therapy boost semaglutide weight loss?

A clinical summary of the study: hormone therapy may be linked to greater weight loss with semaglutide, but the findings are observational and no reason to prescribe hormone therapy for weight management.

We are seeing a consistent signal
Regina Castaneda, Mayo Clinic Florida, lead researcher
Published abstract
NewsNation

‘Wolverine’ peptide claims to accelerate healing and recovery

Broadcast coverage of healing claims draws on the analysis of 1,039 documented users and outside cautions about untested peptides.

People need to understand that there’s a huge difference between peptides that have been rigorously studied and approved as medications, such as insulin and GLP-1 weight-loss drugs, and these newer compounds
Christopher Robinson, Johns Hopkins University School of Medicine
Published study
Advisory Board

GLP-1s may cause patients to lose their hair

A clinical briefing puts uncommon hair-loss signals into context and highlights questions for further investigation.

Clinicians may consider discussing the possibility of hair loss when initiating GLP-1 receptor agonist therapy and monitoring for symptoms during follow-up, particularly in the first year
The study authors
Everyday Health

Combining Hormone Therapy With GLP-1s May Boost Weight Loss for Menopausal Women

Women taking semaglutide with hormone therapy lost a few more pounds on average than those without it; the lead researcher and an outside ob-gyn put the observational finding in context.

Our earlier, smaller studies showed an association between hormone therapy use and greater weight loss in postmenopausal women, and the fact that we see the same signal in a larger, independent cohort should not be overlooked
Regina Castaneda, Mayo Clinic Florida, lead researcher
Published abstract
EurekAlert!

Hormone therapy may increase weight loss effectiveness of GLP-1s

The Menopause Society’s release on the study: hormone therapy was linked to greater and sustained weight loss with semaglutide, with results differing by type of GLP-1.

These findings suggest that hormone therapy may influence how some women respond to GLP-1-based weight loss medications
Stephanie Faubion, The Menopause Society; study co-author
Published abstract
Reuters

Use of untested ‘Wolverine’ peptide backed by US Health Secretary Kennedy on the rise, study finds

Clinical notes document BPC-157 use in 1,039 patients. Incomplete, confounded outcomes cannot establish safety or effectiveness.

There was no placebo or untreated comparator, and there was no standardized indication, formulation, dose, route, treatment duration, or outcome assessment
Flynn McGuire, University of Utah — not involved in the study · The Independent
Published study
Also carried by The Independent
Medscape

Gray-Market Retatrutide: Less Weight Loss, More CV Effects

Coverage of an observational preprint examining weight trajectories and cardiovascular symptoms among documented retatrutide users.

The study provides an important signal that patients are obtaining unapproved retatrutide through unregulated channels, where the product, dose, purity, manufacturing quality, safety, and efficacy cannot be reliably verified
Priya Jaisinghani, NYU Langone Health — not involved in the study
Healthline

Why GLP-1 Drugs May Raise Muscle Loss, Frailty Risk for People Over 65

Outside clinicians discuss uncommon frailty-related events and the importance of interpreting early findings in the context of overall treatment benefits.

The study showed that risk was associated with level of weight loss while also highlighting other important factors such as malnutrition and dehydration. However, the paper did not show that tirzepatide was not safe and, as with many studies, limitations to the research did occur
Kristin Kirkpatrick, Cleveland Clinic — not involved in the study
Healthline

Mounjaro May Lead to Greater Lean Body Mass Loss than Ozempic. Here’s Why

The lean-mass preprint suggests that greater weight loss with tirzepatide may come with more lean tissue lost; an outside surgeon is not surprised.

This finding is not entirely surprising. Tirzepatide is generally more potent than semaglutide, and with greater overall weight loss, you often see a higher degree of lean mass loss as well
Jeffrey Lee, JL Plastic Surgery — not involved in the study
Published study

Key Opinion Leaders (KoLs)

C. Michael Gibson, MD
C. Michael Gibson, MDHarvard Medical School · Baim Institute
“These studies from nference signal that longitudinal, AI-curated evidence can inform prospective studies in profound ways. The broad spectrum of weight-loss-independent benefits revealed by the first series of MAIA publications challenges long-held cardiometabolism assumptions that place glucose lowering and total body weight reduction at the center of therapeutic value. These findings reinforce that incretin biology is organ-specific, durable, and multidimensional.”
nferenceDesigning future studies · June 2026 ↗
Mona Gohara, MD
Mona Gohara, MDYale School of Medicine
“What makes this study interesting is that even after researchers matched patients for how much weight they lost, hair loss remained somewhat more common with tirzepatide: 4.24 percent versus 3.33 percent. That suggests weight loss may not be the entire explanation.”
Women’s HealthOn hair loss beyond weight loss · August 2026 ↗
Kalyanam Shivkumar, MD PhD
Kalyanam Shivkumar, MD PhDUCLA Health
“The weighing scale may be the loudest biomarker of GLP-1 therapy effectiveness, but the heart may be reading a distinct signal of therapeutic benefit. If confirmed prospectively, this finding argues that cardiovascular trials should treat dose exposure, persistence, and organ endpoints as first-class variables rather than assuming weight loss is the major mediator.”
nferenceLooking beyond weight loss · June 2026 ↗
Joshua Zeichner, MD
Joshua Zeichner, MDMount Sinai
“Since the tirzepatide affects more than one receptor, it may have a greater impact on the body than just weight loss. GIP receptors have been identified in the hair follicles and, as the drug binds to these receptors, it may have an effect on the microenvironment surrounding the hair follicles, impacting their activity.”
AllureOn how tirzepatide differs · August 2026 ↗
Clifford Rosen, MD
Clifford Rosen, MDMaineHealth
“The recent publications from nference provide a new roadmap of AI-curated evidence that will almost certainly be used to inform gold standard randomized clinical trials for disorders beyond obesity and type 2 diabetes mellitus.”
nferenceA roadmap for future trials · June 2026 ↗
Preethi Srikanthan, MD
Preethi Srikanthan, MDUCLA Health

Reuters’ account of her comments, not a direct quote

The reduction in lean body mass that accompanies GLP-1-induced weight loss may matter more in older patients because many start with low muscle reserve, said UCLA endocrinologist Dr. Preethi Srikanthan, who was not involved in the research. Whether tirzepatide-associated weight loss leads to clinically important frailty in vulnerable older adults needs to be verified with prospective data and gold-standard frailty assessment methods, she said.
ReutersOn frailty in older adults · July 2026 ↗
Marcelo Montorzi, MDSouthcoast Health
“This may be the first time that decades of body-weight history have been reconstructed from routine patient records at this scale. The finding that GLP-1 super-responders are often the same patients who experienced the most recent acceleration in weight gain is a fundamental observation. It suggests that future cardiometabolism trials should not only ask how much weight a drug reduces, but whether the patient’s prior weight-gain velocity predicts the magnitude, durability, and clinical meaning of response.”
nferenceDecades of weight history · June 2026 ↗
Mir Ali, MD
Mir Ali, MDMemorialCare
“These conditions are rare occurrences, and we should just be more aware of the issues for older adults. By no means does it mean we should not prescribe these medications to people over 65.”
HealthlineOn findings in older adults · July 2026 ↗
Regina Castaneda, MDMayo Clinic Florida
“Interestingly, the effect was stronger with semaglutide than with tirzepatide, which deserves further study and may point to an interaction specific to GLP-1 signaling.”
HealthDayOn hormone therapy and GLP-1s · October 2026 ↗
Manish Kohli, MD
Manish Kohli, MDHuntsman Cancer Institute · University of Utah
“For decades, oncology has studied tumor metabolism, but we have not fully leveraged the patient’s own metabolic trajectory as a clinical signal. These cancer metabotyping studies point to a common hypothesis: host metabolism may influence cancer progression, treatment tolerance, immune response, drug efficacy, and survival in ways that are measurable in routine care. If validated prospectively, weight trajectory and metabolic context could become practical tools for stratifying patients across solid tumors and hematologic malignancies.”
nferenceMetabolic signals in cancer · June 2026 ↗
C. Michael Gibson, MD
C. Michael Gibson, MDHarvard Medical School · Baim Institute
“The analysis gives us a little more hope that there are going to be some people who will not regain weight, that it’s not a lifelong treatment in everyone. We need to better identify who’s going to be successful.”
ReutersOn who keeps the weight off · January 2026 ↗
Joseph Smith, MD PhDJohns Hopkins
“The very promising link of microdose levels of these agents to lower 24-month event-rates for a broad array of cardiovascular endpoints despite very modest weight loss, when taken together with evidence of disproportionate lean muscle loss at higher doses of some agents, only emphasizes the reality that the magnitude and scope of the many and varied impacts of these agents are well beyond their effectiveness at overall weight loss.”
nferenceBeyond weight loss · June 2026 ↗
Susan Massick, MD
Susan Massick, MDOhio State Wexner Medical Center
“Weight loss is linked to hair loss, especially when it’s fast or dramatic”, says Susan Massick, MD, a board-certified dermatologist at The Ohio State University Wexner Medical Center. “GLP-1s are known for helping people to lose weight quickly, which can explain why some patients on tirzepatide and semaglutide were faced with hair loss.”
AllureOn weight loss and hair loss · August 2026 ↗
David Kessler, MD
David Kessler, MDFormer FDA Commissioner
“It’s not the drugs” that cause lasting weight loss, he said. “It’s whether you learn to adjust your eating while you’re on those drugs.”
ReutersOn eating habits after GLP-1s · January 2026 ↗

Research use only. This atlas summarises observational research for a professional audience and is provided as is, without warranty of any kind. It is not medical advice, not a diagnosis and not a recommendation for or against any treatment, and it does not create a doctor–patient relationship. Decisions about care belong with a qualified clinician who knows the patient. Observational findings identify associations rather than cause and effect, and work marked as a preprint or under review has not completed peer review. Any use you make of this material is at your own risk. Your use is governed by the nference terms of use ↗.

About the evidence

The studies in this atlas draw on de-identified patient records. Observational findings identify associations; they do not establish cause and effect. Study status and methods are available in the chapter and paper records. Preprints have not completed peer review. This site is not medical advice.

About the anatomy

The anatomy uses BodyParts3D 4.0, an adult male reference model from the Database Center for Life Science, licensed CC BY 4.0 and simplified for the browser. It is an educational guide to the literature, not a diagnostic or surgical tool. Anatomy sources and attribution ↗